DNA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DNA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.
Ginkgo Bioworks Holdings's Capital Expenditure for the three months ended in Dec. 2023 was $-3.45 Mil. Its Revenue for the three months ended in Dec. 2023 was $34.76 Mil.
Hence, Ginkgo Bioworks Holdings's Capex-to-Revenue for the three months ended in Dec. 2023 was 0.10.
The historical data trend for Ginkgo Bioworks Holdings's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ginkgo Bioworks Holdings Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Capex-to-Revenue | 0.41 | 0.75 | 0.18 | 0.11 | 0.16 |
Ginkgo Bioworks Holdings Quarterly Data | |||||||||||||||
Dec19 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Capex-to-Revenue | Get a 7-Day Free Trial | 0.26 | 0.24 | 0.17 | 0.08 | 0.10 |
For the Biotechnology subindustry, Ginkgo Bioworks Holdings's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Ginkgo Bioworks Holdings's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where Ginkgo Bioworks Holdings's Capex-to-Revenue falls into.
Ginkgo Bioworks Holdings's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
Capex-to-Revenue | = | - Capital Expenditure | / | Revenue |
= | - (-40.801) | / | 251.455 | |
= | 0.16 |
Ginkgo Bioworks Holdings's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as
Capex-to-Revenue | = | - Capital Expenditure | / | Revenue |
= | - (-3.446) | / | 34.755 | |
= | 0.10 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ginkgo Bioworks Holdings (NYSE:DNA) Capex-to-Revenue Explanation
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
Thank you for viewing the detailed overview of Ginkgo Bioworks Holdings's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Jason R Kelly | director, officer: CEO & Founder | 667 MADISON AVENUE, C/O CORVEX MANAGEMENT LP, NEW YORK NY 10065 |
Mark E. Dmytruk | officer: Chief Financial Officer | C/O SOARING EAGLE ACQUISITION CORP., 955 FIFTH AVENUE, NEW YORK NY 10075 |
Barry Canton | 10 percent owner | C/O GINKGO BIOWORKS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210 |
Reshma P. Shetty | director, 10 percent owner, officer: President, COO & Founder | C/O SOARING EAGLE ACQUISITION CORP., 955 FIFTH AVENUE, NEW YORK NY 10075 |
Christian O Henry | director | 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121 |
Harry Sloan | director, officer: CEO, Chairman | 1450 2ND STREET, SUITE 247, SANTA MONICA CA 90401 |
Shyam Sankar | director | C/O PALANTIR TECHNOLOGIES INC., 1200 17TH STREET, FLOOR 15, DENVER CO 80202 |
Steven P. Coen | officer: Chief Accounting Officer | C/O GINKGO BIOWORKS HOLDINGS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210 |
Marie E. Fallon | officer: Chief Accounting Officer | C/O GINKGO BIOWORKS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210 |
Marijn E Dekkers | director | GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210 |
Kathy Hopinkah Hannan | director | ANNALY CAPITAL MANAGEMENT, INC., 1211 AVE. OF THE AMERICAS, NEW YORK NY 10036 |
David C. Ott | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Viking Global Opportunities Parent Gp Llc | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Viking Global Investors Lp | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Viking Global Opportunities Gp Llc | 10 percent owner | 55 RAILROAD AVENUE, GREENWICH CT 06830 |
From GuruFocus
By PRNewswire • 01-10-2024
By PRNewswire • 11-14-2023
By PRNewswire • 10-12-2023
By PRNewswire • 12-19-2023
By PRNewswire • 12-19-2023
By PRNewswire • 11-27-2023
By PRNewswire • 10-16-2023
By PRNewswire • 01-08-2024
By PRNewswire • 01-03-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.